HomeAGIO • NASDAQ
Agios Pharmaceuticals Inc
Follow
$25.76
7.04%
After Hours:(1.01%)+0.26
$26.02
Closed: Apr 4, 4:31:20 PM GMT-4 · USD · NASDAQ · Disclaimer
In the news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 10.73M | 51.06% |
Operating expense | 51.70M | 46.43% |
Net income | -96.52M | -0.61% |
Net profit margin | -899.56 | 33.40% |
Earnings per share | -1.74 | -1.16% |
EBITDA | -123.67M | -17.92% |
Effective tax rate | 8.42% | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 893.71M | 15.03% |
Total assets | 1.66B | 77.48% |
Total liabilities | 122.24M | -3.06% |
Total equity | 1.54B | — |
Shares outstanding | 57.30M | — |
Price to book | 1.03 | — |
Return on assets | -18.09% | — |
Return on capital | -19.03% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | -96.52M | -0.61% |
Cash from operations | -133.17M | -83.71% |
Cash from investing | -49.16M | -151.47% |
Cash from financing | 4.84M | 471.66% |
Net change in cash | -177.48M | -843.48% |
Free cash flow | -108.06M | -155.48% |
Previous close
$27.71
Day range
$25.26 - $27.86
Year range
$25.26 - $62.58
Market cap
1.48B USD
Avg Volume
700.96K
P/E ratio
2.21
Dividend yield
-
Primary exchange
NASDAQ
About
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
Founded
2008
Website
Employees
487
